About GeneDx
GeneDx is a publicly listed company based in Gaithersburg (United States) founded in 2000, and was acquired by Sema4 in January 2022. Genetic testing for inherited disorders is provided by the company. The company has 1,000 employees. GeneDx has completed 1 acquisition, including Fabric Genomics. Its website genedx.com draws about 129 thousand monthly visits. GeneDx offers products and services including XomeDx, GenomeSeqDx, and GenomeXpress. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is GeneDx LLC. Its competitors include Natera, ArcherDX and Variantyx; 3 of its 3 listed competitors have raised funding.
Company details
Provider of genetic testing for inherited disorders. The company has CLIA certified labs that carry out genetic tests covering a range of medical specialties including cardiology, endocrinology, metabolic disorders, developmental disorders, hematology, immunology, oncology (hereditary cancer syndromes), among others. The company offers whole-exome sequencing with or without mitochondrial DNA sequencing, with or without reporting of incidental findings in the clinical reports.
- Annual Revenue$427.54 M (USD)39.97as on Dec 31, 2025
- Net Profit-$21.02 M (USD)59.8as on Dec 31, 2025
- EBITDA$13.42 M (USD)2628.05as on Dec 31, 2025
- InvestorsBioreference
& 1 more
- Employee Count1,000
- Investments & Acquisitions
- Acquired by
Products & Services of GeneDx
GeneDx offers a comprehensive portfolio of products and services, including XomeDx, GenomeSeqDx, and GenomeXpress.
Test for diagnosing genetic disorders with higher yield than alternatives.
Comprehensive test including mitochondrial analysis for rare diseases.
Accelerates diagnosis for infants in intensive care units.
Apps and channels of GeneDx
its YouTube channel GeneDx has 809 subscribers and 30 videos.
Videos from GeneDx
The most watched videos on GeneDx's YouTube channel, GeneDx (809 subscribers). Click a video to play it here.
More on GeneDx.
Investors in GeneDx
GeneDx has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Bioreference and GeneDx.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Pathology laboratory services are operated through a nationwide chain. | 1981 | bioreference.com | Elmwood Park, United States | |
Genome-based diagnostic solutions for reproductive health and oncology are provided. | 2017 | sema4.com | Stamford, United States |
Investor details for GeneDx
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of GeneDx
74 people are tracked at GeneDx (37 in leadership, 6 in board & advisors, 31 in team); the tracked headcount is 1,000.
| Name | Role | Group |
|---|---|---|
Shanice W. | Senior Manager, Strategic Finance Business Partner | Leadership |
Lisa Gurry | Chief Business Officer | Leadership |
Megan Marshall | Director, Operations Management And Analytics | Leadership |
Katie Belton | Director, Client Experience - Client Growth & Success | Leadership |
Ashley McQuistan | Associate Director, People Business Partner | Leadership |
Erika Myszynski | Director Of Digital Marketing | Leadership |
Adam Meinel | Head Of Enterprise Applications | Leadership |
Alexandre Fedtsov | Head Of Data Warehouse | Leadership |
Stephanie Kahan | Senior Vice President, Marketing, Communications And Brand | Leadership |
Gabriele Richard | Medical Director | Leadership |
Richard Lusk | Senior Vice President, Growth Finance | Leadership |
Molly Robbins | Director - Process Improvement | Leadership |
Steve McMillan | Head Of Operational Finance | Leadership |
Heather Milligan-Day | Director, Supply & Distribution | Leadership |
Joan Mikardos | Vp, Commercialization And Planning | Leadership |
Audra Bettinelli | Regional Sales Director - South Central | Leadership |
Chaylene Guinto | Head Of Operations Strategy And Analytics | Leadership |
Bryan Dechairo | Chief Operating Officer | Leadership |
Prabhu Devadasan | Sr Director Strategy Forecasting | Leadership |
Paul Newby | VP Of IT | Leadership |
54 more people are available in the full profile.
Complete people profiles for GeneDx
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of GeneDx
GeneDx is a publicly listed company on the NASDAQ with ticker symbol WGS in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Nov 2020
- Listed onNASDAQ: WGS
- Listed entityGeneDx Holdings Corp.
- Exchange sectorHealth services
- ISINUS81663L2007
- Share price$64.96 (+1.79% on the day) · 2026-10-13
- Market capitalisation$1.94B
- Price to earnings2,713.3
- EPS (diluted, trailing year)$-3.63
- Volume (last session)527,131
Financials of GeneDx
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $427.5M | -$21.0M | $13.4M |
| 2024 | $305.4M | -$52.3M | $492,000 |
| 2023 | $202.6M | -$175.8M | -$127.8M |
| 2022 | $234.7M | -$549.0M | -$355.2M |
| 2021 | $212.2M | -$245.4M | -$417.3M |
Detailed financial statements for GeneDx
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GeneDx
GeneDx has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Fabric Genomics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
AI-based disease diagnosis and genomic analysis tool for providers | fabricgenomics.com | Oakland, United States | 0 | Apr 2025 | $51M |
Complete acquisition details for GeneDx
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of GeneDx
5 dated milestones of GeneDx across 25 years, from founding to its latest funding, stage changes and deals.
- Founded GeneDx is founded.
- Exit Acquired by Bioreference.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Sema4.
- Acquisition Acquires Fabric Genomics.
Competitors of GeneDx
GeneDx has 3 listed competitors in our database, 3 of them funded. They include Natera, ArcherDX and Variantyx.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| natera.com | 2004 | Redwood, United States | $152.1M | 3,293 | Developer of cell-free DNA testing for oncology, women’s health, and organ health | |
| archerdx.com | 2013 | Boulder, United States | $152.6M | 429 | Molecular cancer diagnostic products are developed using patented AMP technology. | |
| variantyx.com | 2014 | Boston, United States | $110.5M | 122 | Genomics data analysis platform for healthcare diagnostics is offered. |
Detailed competitors of GeneDx
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of GeneDx
The website of GeneDx (genedx.com) receives about 129.4K visits a month.
- Monthly visits129.4K
▲ 34.8% vs previous month
Websites whose visitors overlap most with GeneDx. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
nsgc.org | nsgc.org | 100% | #681,340 | – | |
| counsyl.com | 99% | 97.8K | #378,239 | View details | |
| pathway.com | 91% | 77.6K | #436,968 | View details | |
| kimballgenetics.com | 89% | View details | |||
| navigenics.com | 89% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 29 similar websites and full traffic analytics for GeneDx
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 29 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as GeneDx (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genedx
Complete news archive for GeneDx
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GeneDx
GeneDx was founded in 2000.
GeneDx is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
GeneDx has 1,000 employees.
Annual revenue of GeneDx is $427.54M as on Dec 31, 2025.
Provider of genetic testing for inherited disorders. The company has CLIA certified labs that carry out genetic tests covering a range of medical specialties including cardiology, endocrinology, metabolic disorders, developmental disorders, hematology, immunology, oncology (hereditary cancer syndromes), among others. The company offers whole-exome sequencing with or without mitochondrial DNA sequencing, with or without reporting of incidental findings in the clinical reports.
GeneDx offers XomeDx, GenomeSeqDx, and GenomeXpress.
Yes, GeneDx is publicly traded on NASDAQ under the ticker symbol WGS.
GeneDx has made 1 acquisition, including Fabric Genomics.
GeneDx has 2 investors. Key investors include Bioreference, and GeneDx.
GeneDx operates through Genedx Llc.
Yes. GeneDx was acquired by Sema4 in January 2022.